This site is intended for healthcare professionals
  • Home
  • /
  • Drugs
  • /
  • V VARIOUS
  • /
  • V03
  • /
  • V03A
  • /
  • V03AB
  • /
  • V03AB25
  • /
  • Flumazenil 100 micrograms/ml solution for injectio...
Drug information

Flumazenil

POM
Read time: 13 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Flumazenil is indicated for the complete or partial reversal of the central sedative effects of benzodiazepines. It may therefore be used in anaesthesia and in the intensive care in the following situations:

In anaesthesia

- Termination of hypnosedative effects in general anaesthesia induced and/or maintained with benzodiazepines in hospitalised patients.

- Reversal of benzodiazepine sedation in short-term diagnostic and therapeutic procedures in ambulatory patients and hospitalised patients.

- For the reversal of conscious sedation induced with benzodiazepines in children > 1 year of age.

In intensive care situations

- For the specific reversal of the central effects of benzodiazepines, in order to restore spontaneous respiration.

- For diagnosis and treatment of intoxications or overdose with only or mainly benzodiazepines (see section 4.4).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).